Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Completed · NCT05673967
Conditions: Relapsed and Refractory Multiple Myeloma (RRMM)
At a glance
- Research payments reported, 2025
- $6,000
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Non-Interventional (other)
- Dates
- Started 2023-01-09; completion 2025-03-28
- Results posted
- Not yet
Primary Objective: 1\. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after meeting the following criteria: (1) have either (a) at least three prior lines (3L) and are triple-class exposed (TCE), or (b) are triple-class refractory (TCR), and (2) meet similar inclusion/exclusion criteria to patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial. Secondary Objectives: 1. To describe additional outcomes (duration of response \[DOR\], progression-free survival \[PFS\], overall survival \[OS\], and time to next treatment \[TT…
From ClinicalTrials.gov, last updated 2025-04-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $6,000 in research payments for this study in 2025 (1 payments).
Products named: Lynozyfic
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $6,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.